We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Protagonist Therapeutics Inc | NASDAQ:PTGX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.55 | 2.15% | 26.09 | 24.00 | 27.61 | 26.585 | 25.745 | 26.20 | 355,731 | 01:00:00 |
From May 2021 to May 2024
By Matt Grossman
Protagonist Therapeutics Inc.'s clinical studies for its rusfertide drug have been placed on a clinical hold by the U.S. Food and Drug Administration because of a recent finding in a mouse-model study, the company said Friday.
Benign and malignant skin tumors were observed in the mouse-model study, Protagonist said.
Dosing of patients has been put on hold, the Newark, Calif.-based pharmaceutical company said. Rusfertide was being tested in three Phase 2 trials, to treat polycthemia vera--a type of blood caner--and hereditary hemochromatosis, or iron overload.
Protagonist said it will work with the FDA to make any necessary updates to study protocols.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 17, 2021 07:36 ET (11:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Protagonist Therapeutics Chart |
1 Month Protagonist Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
